Q4 saw a 45% net revenue increase to $10.1M, with prescription shipments up 25% and strong cash flow improvements. Gross-to-net yield rose to 22%, and cost-saving initiatives plus IP expansion position the business for continued growth and value creation.Based on Botanix Pharmaceuticals Limited [BO…
Sofdra prescriptions and net revenue surged in Q4 FY26, with gross-to-net yield improving to 22%. Operating cash outflow dropped 54% as sales and cash reserves grew. Patent protection and a new API supplier position the company for continued growth and margin expansion.Original document: Botanix Ph…
Prescriptions and net revenue for Sofdra surged in Q4 FY26, with improved gross-to-net yield and a significant reduction in operating cash outflow. Cash reserves were strengthened by a capital raise, and strategic initiatives are underway to optimize sales force, supply chain, and IP portfolio.Orig…
